Tim Tasker

710 total citations
23 papers, 490 citations indexed

About

Tim Tasker is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Tim Tasker has authored 23 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Pharmacology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Tim Tasker's work include Neuroscience and Neuropharmacology Research (5 papers), Receptor Mechanisms and Signaling (5 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). Tim Tasker is often cited by papers focused on Neuroscience and Neuropharmacology Research (5 papers), Receptor Mechanisms and Signaling (5 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). Tim Tasker collaborates with scholars based in United Kingdom, United States and Australia. Tim Tasker's co-authors include Graham Allen, G. Mellows, Jesper Hallas, Søren H. Sindrup, Lars F. Gram, Barry D. Zussman, Erik Skjelbo, Kim Brøsen, Ann Allen and Alastair Brown and has published in prestigious journals such as The American Journal of Medicine, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

Tim Tasker

23 papers receiving 462 citations

Peers

Countries citing papers authored by Tim Tasker

Since Specialization

Citations

This map shows the geographic impact of Tim Tasker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Tasker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Tasker more than expected).

Fields of papers citing papers by Tim Tasker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Tasker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Tasker. The network helps show where Tim Tasker may publish in the future.

Co-authorship network of co-authors of Tim Tasker

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Tasker. A scholar is included among the top collaborators of Tim Tasker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Tasker. Tim Tasker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects 2021 ·Drugs in R&D ·C. J. G. Bakker, Jasper van der Aart, Geert Labots, (unknown), David M. Cross, Erica S. Klaassen, Stephen J. Dickinson, Tim Tasker, Geert Jan Groeneveld	5
2	Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study 2021 ·Alzheimer s Research & Therapy ·C. J. G. Bakker, Tim Tasker, (unknown), Ellen P. Hart, Erica S. Klaassen, Robert J. Doll, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona H. Marshall, David M. Cross, Geert Jan Groeneveld, Pradeep J. Nathan	13
3	Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M₁‐acetylcholine receptor agonist: A randomized cross‐over trial 2021 ·British Journal of Clinical Pharmacology ·C. J. G. Bakker, (unknown), (unknown), Ellen P. Hart, Erica S. Klaassen, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona H. Marshall, Jasper Stevens, David M. Cross, Tim Tasker, Pradeep J. Nathan, Geert Jan Groeneveld	3
4	First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M₁‐receptor partial agonist for the treatment of dementias 2020 ·British Journal of Clinical Pharmacology ·C. J. G. Bakker, Tim Tasker, (unknown), Ellen P. Hart, Erica S. Klaassen, (unknown), Thalia F. van der Doef, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona H. Marshall, David M. Cross, Geert Jan Groeneveld, Pradeep J. Nathan	13
5	Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders 2019 ·Drug Discovery Today ·Daniel Erskine, John‐Paul Taylor, Geor Bakker, Alastair Brown, Tim Tasker, Pradeep J. Nathan	38
6	The partial positive allosteric GABAA receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients 2009 ·Sleep Medicine ·James K. Walsh, (unknown), (unknown), Tim Tasker, (unknown)	16
7	Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness 2009 ·Sleep Medicine ·James K. Walsh, (unknown), (unknown), Tim Tasker, (unknown)	16
8	Metabolism and disposition of¹⁴C-granisetron in rat, dog and man after intravenous and oral dosing 1994 ·Xenobiotica ·S. E. Clarke, Nigel Austin, J. C. Bloomer, R. E. Haddock, (unknown), F. J. Hollis, (unknown), P. C. Shardlow, Tim Tasker, (unknown), Graham Allen	24
9	Effects of dietary protein source on plasma lipids, HMG CoA reductase activity, and hepatic glutathione levels in gerbils, 1993 ·The Journal of Nutritional Biochemistry ·Tim Tasker	24
10	A comparison of sexual behaviour and risk behaviour for HIV infection between women in three clinical settings. 1993 ·Sexually Transmitted Infections ·K W Radcliffe, Tim Tasker, (unknown), (unknown), (unknown)	7
11	Risk profiles for genital infection in women. 1993 ·Sexually Transmitted Infections ·(unknown), Tim Tasker, K D MacRae	18
12	The relationship between paroxetine and the sparteine oxidation polymorphism 1992 ·Clinical Pharmacology & Therapeutics ·Søren H. Sindrup, Kim Brøsen, Lars F. Gram, Jesper Hallas, Erik Skjelbo, Ann Allen, Graham Allen, (unknown), G. Mellows, Tim Tasker, Barry D. Zussman	173
13	Effects of the Potassium Channel Activator, Cromakalim, on Arterial and Cardiac Responses to Norepinephrine, Angiotensin II, and Isoproterenol in Normotensive Men 1991 ·Journal of Cardiovascular Pharmacology ·Paul Nguyen, (unknown), (unknown), Tim Tasker, Frans H. H. Leenen	5
14	Pharmacokinetics of intravenous amoxycillin and potassium clavulanate in seriously ill children 1990 ·Journal of Antimicrobial Chemotherapy ·(unknown), N D Barnes, Tim Tasker, (unknown)	13
15	The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. 1990 ·PubMed ·(unknown), (unknown), (unknown), (unknown), (unknown), Tim Tasker	61
16	BRL 20330, an oral prodrug of temocillin: bioavailability studies in man 1986 ·Journal of Antimicrobial Chemotherapy ·MICHAEL J. BASKER, D. J. Merrikin, Roger J. Ponsford, B Slocombe, Tim Tasker	3
17	Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges 1986 ·Antimicrobial Agents and Chemotherapy ·Johan Bakken, Johan N. Bruun, Peter Gaustad, Tim Tasker	27
18	Safety of ticarcillin disodium/potassium clavulanate 1986 ·Journal of Antimicrobial Chemotherapy ·Tim Tasker, Andrew Cockburn, David Jackson, G. Mellows, David White	3
19	Human pharmacokinetics of temocillin (BRL 17421) side chain epimers 1985 ·Journal of Antimicrobial Chemotherapy ·(unknown), (unknown), G. Mellows, B Slocombe, (unknown), Tim Tasker	4
20	Clinical pharmacology and safety evaluation of timentin 1985 ·The American Journal of Medicine ·(unknown), Andrew Cockburn, (unknown), P. F. Langley, Tim Tasker, David J. White	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact